Abstract Owing to its involvement in extracellular matrix–glial cell interactions, discoidin domain receptor 2 (DDR2) has emerged as a promising pharmacological target in various human diseases, including cancers and neurodegenerative disorders. Two allosteric inhibitors, WRG-28 and DDR2-IN-1, selectively target DDR2.
Mathieu Molimard
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Mathieu
Contact Mathieu, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack